Comparación del Hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México

Content Provider	Semantic Scholar
Author	Ramos-Peñafiel, Christian Omar Cabrera-García, Álvaro Rozen-Fuller, Etta González-León, Guadalupe Balderas, Carolina Kassack-Ipiña, Juan Julio Castellanos-Sinco, Humberto Martínez-Murillo, Carlos Montaño-Figueroa, Efreen Horacio Martínez-Tovar, Adolfo Olarte-Carrillo, Irma Santoyo-Sánchez, Adrián Collazo-Jaloma, Juan
Copyright Year	2014
Abstract	In order to assess the mortality and toxicity of the Hyper-CVAD protocol used as first-line treatment of acute lymphoblastic leukemia, a retrospective cohort study was performed in patients less than 40 years of age from March to September 2011 treated with Hyper-CVAD regimen. Mortality and toxicity was compared with the results of patients treated with the institutional HGMLAL07 regimen between 2009-2012. 18 patients were included; the median age was 26 years old. Complete remissions (67.7% versus 81.9%) as well as one-year (40% versus 62%) and 2 year survival rates (18% versus 34%) were lower with the Hyper-CVAD regimen. By selecting only patients younger than 35 years, the effectiveness of Hyper-CVAD was also lower. In our experience and because of its high cost and toxicity, the Hyper-CVAD regimen should be limited to patients with relapsed or refractory leukemia.
Starting Page	525
Ending Page	529
Page Count	5
File Format	PDF HTM / HTML
DOI	10.17843/rpmesp.2014.313.91
Volume Number	31
Alternate Webpage(s)	http://www.scielosp.org/pdf/rpmesp/v31n3/a18v31n3.pdf
Alternate Webpage(s)	https://www.redalyc.org/pdf/363/36333049018.pdf
Alternate Webpage(s)	https://doi.org/10.17843/rpmesp.2014.313.91
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article